BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 19794091)

  • 1. Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma.
    Sapra P; Kraft P; Mehlig M; Malaby J; Zhao H; Greenberger LM; Horak ID
    Haematologica; 2009 Oct; 94(10):1456-9. PubMed ID: 19794091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.
    Sapra P; Zhao H; Mehlig M; Malaby J; Kraft P; Longley C; Greenberger LM; Horak ID
    Clin Cancer Res; 2008 Mar; 14(6):1888-96. PubMed ID: 18347192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.
    Sapra P; Kraft P; Pastorino F; Ribatti D; Dumble M; Mehlig M; Wang M; Ponzoni M; Greenberger LM; Horak ID
    Angiogenesis; 2011 Sep; 14(3):245-53. PubMed ID: 21452059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.
    Pastorino F; Loi M; Sapra P; Becherini P; Cilli M; Emionite L; Ribatti D; Greenberger LM; Horak ID; Ponzoni M
    Clin Cancer Res; 2010 Oct; 16(19):4809-21. PubMed ID: 20702613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.
    Patnaik A; Papadopoulos KP; Tolcher AW; Beeram M; Urien S; Schaaf LJ; Tahiri S; Bekaii-Saab T; Lokiec FM; Rezaï K; Buchbinder A
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1499-506. PubMed ID: 23543270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies.
    Kurzrock R; Goel S; Wheler J; Hong D; Fu S; Rezai K; Morgan-Linnell SK; Urien S; Mani S; Chaudhary I; Ghalib MH; Buchbinder A; Lokiec F; Mulcahy M
    Cancer; 2012 Dec; 118(24):6144-51. PubMed ID: 22674635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers.
    Zhao H; Rubio B; Sapra P; Wu D; Reddy P; Sai P; Martinez A; Gao Y; Lozanguiez Y; Longley C; Greenberger LM; Horak ID
    Bioconjug Chem; 2008 Apr; 19(4):849-59. PubMed ID: 18370417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishing SCID mouse models of B-cell non-Hodgkin's lymphoma.
    Yan JS; Chen XY; Li WP; Yang Y; Song ZL
    Ai Zheng; 2009 Feb; 28(2):181-3. PubMed ID: 19550134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors.
    Norris RE; Shusterman S; Gore L; Muscal JA; Macy ME; Fox E; Berkowitz N; Buchbinder A; Bagatell R
    Pediatr Blood Cancer; 2014 Oct; 61(10):1792-7. PubMed ID: 24962521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice.
    Lei S; Chien PY; Sheikh S; Zhang A; Ali S; Ahmad I
    Anticancer Drugs; 2004 Sep; 15(8):773-8. PubMed ID: 15494639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, characterization, and antitumor evaluation of the albumin-SN38 conjugate.
    Yao Y; Su X; Xie Y; Wang Y; Kang T; Gou L; Yi C; Yang J
    Anticancer Drugs; 2013 Mar; 24(3):270-7. PubMed ID: 23233044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete regression of xenograft tumors using biodegradable mPEG-PLA-SN38 block copolymer micelles.
    Lu L; Zheng Y; Weng S; Zhu W; Chen J; Zhang X; Lee RJ; Yu B; Jia H; Qin L
    Colloids Surf B Biointerfaces; 2016 Jun; 142():417-423. PubMed ID: 26994941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, characterization, and evaluation of mPEG-SN38 and mPEG-PLA-SN38 micelles for cancer therapy.
    Xie J; Zhang X; Teng M; Yu B; Yang S; Lee RJ; Teng L
    Int J Nanomedicine; 2016; 11():1677-86. PubMed ID: 27217746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two self-assembled macromolecular prodrug micelles with different conjugate positions of SN38 for enhancing antitumor activity.
    Liu Y; Piao H; Gao Y; Xu C; Tian Y; Wang L; Liu J; Tang B; Zou M; Cheng G
    Int J Nanomedicine; 2015; 10():2295-311. PubMed ID: 25848251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Hydrophilic Camptothecin Derivatives Conjugated to Branched Glycerol Trimer Suppress Tumor Growth without Causing Diarrhea in Murine Xenograft Models of Human Lung Cancer.
    Tsuchihashi Y; Abe S; Miyamoto L; Tsunematsu H; Izumi T; Hatano A; Okuno H; Yamane M; Yasuoka T; Ikeda Y; Tsuchiya K
    Mol Pharm; 2020 Apr; 17(4):1049-1058. PubMed ID: 32068412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan.
    Sepehri N; Rouhani H; Tavassolian F; Montazeri H; Khoshayand MR; Ghahremani MH; Ostad SN; Atyabi F; Dinarvand R
    Int J Pharm; 2014 Aug; 471(1-2):485-97. PubMed ID: 24879937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors.
    Nguyen F; Guan P; Guerrero DT; Kolla V; Naraparaju K; Perry LM; Soberman D; Pressly BB; Alferiev IS; Chorny M; Brodeur GM
    Cancer Res; 2020 Oct; 80(19):4258-4265. PubMed ID: 32839252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid nanoparticles loaded with 7-ethyl-10-hydroxycamptothecin-phospholipid complex: in vitro and in vivo studies.
    Liu H; Lu H; Liao L; Zhang X; Gong T; Zhang Z
    Drug Deliv; 2015; 22(6):701-9. PubMed ID: 24625262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma.
    Iyer R; Croucher JL; Chorny M; Mangino JL; Alferiev IS; Levy RJ; Kolla V; Brodeur GM
    Cancer Lett; 2015 May; 360(2):205-12. PubMed ID: 25684664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro cytotoxicity, pharmacokinetics and tissue distribution in rats of MXN-004, a novel conjugate of polyethylene glycol and SN38.
    Zhou S; Li N; Wang X; Li C; Tian F; Ren S; Zhang Y; He Y; Qiu Z; Zhao D; Chen X
    Xenobiotica; 2014 Jun; 44(6):562-9. PubMed ID: 24308437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.